Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

研究团队还进行了一项前瞻性临床试验，结果显示，L-鸟氨酸可显著提升乌司奴单抗在克罗恩病患者中的治疗效果。该研究首次建立了“微生物-代谢物-免疫靶点”调控网络，为炎症性肠病（IBD）的 精准 治疗提供新策略。

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

该研究是由上海交通大学医学院附属仁济医院消化科研究员洪洁及其团队主导，论文共同第一作者为仁济医院消化科硕士研究生王振宇，博士研究生蒋怡、宁立军，四川省人民医院消化内科医师、博士后朱小强以及中南大学湘雅三医院消化内科主任医师田力。中南大学湘雅三医院消化 ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...